These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9183140)

  • 61. Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan.
    Doyle CA; McDougle CJ
    Dialogues Clin Neurosci; 2012 Sep; 14(3):263-79. PubMed ID: 23226952
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth.
    Pringsheim T; Doja A; Belanger S; Patten S;
    Paediatr Child Health; 2011 Nov; 16(9):590-8. PubMed ID: 23115503
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.
    Woods SW; Morgenstern H; Saksa JR; Walsh BC; Sullivan MC; Money R; Hawkins KA; Gueorguieva RV; Glazer WM
    J Clin Psychiatry; 2010 Apr; 71(4):463-74. PubMed ID: 20156410
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study.
    Masi G; Cosenza A; Millepiedi S; Muratori F; Pari C; Salvadori F
    CNS Drugs; 2009; 23(6):511-21. PubMed ID: 19480469
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The role of antipsychotics in the management of behavioural symptoms in children and adolescents with autism.
    Malone RP; Waheed A
    Drugs; 2009; 69(5):535-48. PubMed ID: 19368416
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Trial design challenges when combining medication and parent training in children with pervasive developmental disorders.
    Scahill L; Aman MG; McDougle CJ; Arnold LE; McCracken JT; Handen B; Johnson C; Dziura J; Butter E; Sukhodolsky D; Swiezy N; Mulick J; Stigler K; Bearss K; Ritz L; Wagner A; Vitiello B
    J Autism Dev Disord; 2009 May; 39(5):720-9. PubMed ID: 19096921
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents.
    Canitano R; Scandurra V
    Neuropsychiatr Dis Treat; 2008 Aug; 4(4):723-30. PubMed ID: 19043516
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders.
    Aman MG; Farmer CA; Hollway J; Arnold LE
    Child Adolesc Psychiatr Clin N Am; 2008 Oct; 17(4):713-38, vii. PubMed ID: 18775366
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Evidence-based comprehensive treatments for early autism.
    Rogers SJ; Vismara LA
    J Clin Child Adolesc Psychol; 2008 Jan; 37(1):8-38. PubMed ID: 18444052
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Antipsychotics in the treatment of autism.
    Posey DJ; Stigler KA; Erickson CA; McDougle CJ
    J Clin Invest; 2008 Jan; 118(1):6-14. PubMed ID: 18172517
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial.
    Miral S; Gencer O; Inal-Emiroglu FN; Baykara B; Baykara A; Dirik E
    Eur Child Adolesc Psychiatry; 2008 Feb; 17(1):1-8. PubMed ID: 18080171
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study.
    Gencer O; Emiroglu FN; Miral S; Baykara B; Baykara A; Dirik E
    Eur Child Adolesc Psychiatry; 2008 Jun; 17(4):217-25. PubMed ID: 18026891
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Risperidone for autism spectrum disorder.
    Jesner OS; Aref-Adib M; Coren E
    Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD005040. PubMed ID: 17253538
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Children with schizophrenia: clinical picture and pharmacological treatment.
    Masi G; Mucci M; Pari C
    CNS Drugs; 2006; 20(10):841-66. PubMed ID: 16999454
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment.
    Gebhardt S; Härtling F; Hanke M; Mittendorf M; Theisen FM; Wolf-Ostermann K; Grant P; Martin M; Fleischhaker C; Schulz E; Remschmidt H
    Eur Child Adolesc Psychiatry; 2006 Oct; 15(7):371-82. PubMed ID: 16648965
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A crossover study of risperidone in children, adolescents and adults with mental retardation.
    Hellings JA; Zarcone JR; Reese RM; Valdovinos MG; Marquis JG; Fleming KK; Schroeder SR
    J Autism Dev Disord; 2006 Apr; 36(3):401-11. PubMed ID: 16596465
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Aripiprazole for the treatment of Tourette's disorder.
    Padala PR; Qadri SF; Madaan V
    Prim Care Companion J Clin Psychiatry; 2005; 7(6):296-9. PubMed ID: 16498492
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Advances in drug treatments for children and adolescents with autism and other pervasive developmental disorders.
    Malone RP; Gratz SS; Delaney MA; Hyman SB
    CNS Drugs; 2005; 19(11):923-34. PubMed ID: 16268664
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacotherapy of pervasive developmental disorders in children and adolescents.
    Masi G
    CNS Drugs; 2004; 18(14):1031-52. PubMed ID: 15584771
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effective treatment for mental disorders in children and adolescents.
    Burns BJ; Hoagwood K; Mrazek PJ
    Clin Child Fam Psychol Rev; 1999 Dec; 2(4):199-254. PubMed ID: 11225935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.